Skip to main content
Premium Trial:

Request an Annual Quote

Sensigen Options Rights to Lupus Dx Biomarkers from Univ. of Michigan

NEW YORK (GenomeWeb News) — Sensigen has acquired an option from the University of Michigan to exclusively license a set of epigenetic biomarkers that can detect and monitor lupus, the company said this week.
The technology covered under the license is a panel of biomarkers of epigenetic variations of genes and related research assays linked to lupus, the company said.
These biomarkers were developed by Bruce Richardson, professor of medicine at the University of Michigan and the chief of rheumatology at Ann Arbor Veterans Hospital, who “discovered that the levels of methylation of certain genes were closely associated with the onset of lupus,” the company said.
Current methods for monitoring and detecting the autoimmune disease measure levels of antibodies and proteins known to fluctuate in the blood.
Richardson said that an assay using this panel and based on Sensigen’s AttoSense “has the potential to achieve an unprecedented level of diagnostic sensitivity and specificity” for diagnosing and managing lupus.
Financial terms of the agreement were not released.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.